Advanced search
Publication Cover
Current Medical Research and Opinion Volume 31, 2015 - Issue 8
Submit an article Journal homepage
253
Views
3
CrossRef citations to date
0
Altmetric
Original article

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Nanxin LiAnalysis Group Inc., Boston, MA, USACorrespondence[email protected]
,
Yanni HaoNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Jipan XieAnalysis Group Inc., New York, NY, USA
,
Peggy L. LinAnalysis Group Inc., Boston, MA, USA
,
Zhou ZhouAnalysis Group Inc., Boston, MA, USA
,
Yichen ZhongAnalysis Group Inc., Boston, MA, USA
,
James E. SignorovitchAnalysis Group Inc., Boston, MA, USA
&
Eric Q. WuAnalysis Group Inc., Boston, MA, USA
 show all
Pages 1573-1582 | Accepted 10 Jun 2015, Published online: 20 Aug 2015

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Annie Guérin, Yanni Hao, Derek Tang, Miranda Peeples, Anna Fang, Andrew Kageleiry, Valerie Koo, Nanxin Li & Eric Q. Wu. (2016) Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opinion on Pharmacotherapy 17:9, pages 1189-1196.
Read now

Articles from other publishers (2)

Monika Parisi, Corey Pelletier, Dasha Cherepanov & Michael S Broder. (2018) Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review . Journal of Comparative Effectiveness Research 7:1, pages 67-83.
Crossref
Chengcheng Gong, Yannan Zhao, Biyun Wang, Xichun Hu, Zhonghua Wang, Jian Zhang & Sheng Zhang. (2017) Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget 8:35, pages 59810-59822.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.